Abstract
The G-protein coupled receptors for Δ9-tetrahydrocannabinol, the major psychoactive principle of marijuana, are known as cannabinoid receptors of type 1 (CB1) and 2 (CB2) and play important functions in degenerative and inflammatory disorders of the central nervous system. Whilst CB1 receptors are mostly expressed in neurons, where they regulate neurotransmitter release and synaptic strength, CB2 receptors are found mostly in glial cells and microglia, which become activated and over-express these receptors during disorders such as Alzheimers disease, multiple sclerosis, amyotropic lateral sclerosis, Parkinsons disease, and Huntingtons chorea. The neuromodulatory actions at CB1 receptors by endogenous agonists (‘endocannabinoids’), of which anandamide and 2- arachidonoylglycerol are the two most studied representatives, allows them to counteract the neurochemical unbalances arising during these disorders. In contrast, the immunomodulatory effects of these lipophilic mediators at CB2 receptors regulate the activity and function of glia and microglia. Indeed, the level of expression of CB1 and CB2 receptors or of enzymes controlling endocannabinoid levels, and hence the concentrations of endocannabinoids, undergo time- and brain region-specific changes during neurodegenerative and neuroinflammatory disorders, with the initial attempt to counteract excitotoxicity and inflammation. Here we discuss this plasticity of the endocannabinoid system during the aforementioned central nervous system disorders, as well as its dysregulation, both of which have opened the way to the use of either direct and indirect activators or blockers of CB1 and CB2 receptors for the treatment of the symptoms or progression of these diseases.
Keywords: Δ9-tetrahydrocannabinol, cannabinoid receptors, Alzheimer's disease, multiple sclerosis, amyotropic lateral sclerosis, Parkinson's disease, Huntington's chorea, neuroinflammatory disorders
CNS & Neurological Disorders - Drug Targets
Title: Cannabinoid Receptors and Endocannabinoids: Role in Neuroinflammatory and Neurodegenerative Disorders
Volume: 9 Issue: 5
Author(s): Tiziana Bisogno and Vincenzo Di Marzo
Affiliation:
Keywords: Δ9-tetrahydrocannabinol, cannabinoid receptors, Alzheimer's disease, multiple sclerosis, amyotropic lateral sclerosis, Parkinson's disease, Huntington's chorea, neuroinflammatory disorders
Abstract: The G-protein coupled receptors for Δ9-tetrahydrocannabinol, the major psychoactive principle of marijuana, are known as cannabinoid receptors of type 1 (CB1) and 2 (CB2) and play important functions in degenerative and inflammatory disorders of the central nervous system. Whilst CB1 receptors are mostly expressed in neurons, where they regulate neurotransmitter release and synaptic strength, CB2 receptors are found mostly in glial cells and microglia, which become activated and over-express these receptors during disorders such as Alzheimers disease, multiple sclerosis, amyotropic lateral sclerosis, Parkinsons disease, and Huntingtons chorea. The neuromodulatory actions at CB1 receptors by endogenous agonists (‘endocannabinoids’), of which anandamide and 2- arachidonoylglycerol are the two most studied representatives, allows them to counteract the neurochemical unbalances arising during these disorders. In contrast, the immunomodulatory effects of these lipophilic mediators at CB2 receptors regulate the activity and function of glia and microglia. Indeed, the level of expression of CB1 and CB2 receptors or of enzymes controlling endocannabinoid levels, and hence the concentrations of endocannabinoids, undergo time- and brain region-specific changes during neurodegenerative and neuroinflammatory disorders, with the initial attempt to counteract excitotoxicity and inflammation. Here we discuss this plasticity of the endocannabinoid system during the aforementioned central nervous system disorders, as well as its dysregulation, both of which have opened the way to the use of either direct and indirect activators or blockers of CB1 and CB2 receptors for the treatment of the symptoms or progression of these diseases.
Export Options
About this article
Cite this article as:
Bisogno Tiziana and Di Marzo Vincenzo, Cannabinoid Receptors and Endocannabinoids: Role in Neuroinflammatory and Neurodegenerative Disorders, CNS & Neurological Disorders - Drug Targets 2010; 9 (5) . https://dx.doi.org/10.2174/187152710793361568
DOI https://dx.doi.org/10.2174/187152710793361568 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents Relating to siRNAs and Therapeutic Strategies for Genetic Diseases
Recent Patents on DNA & Gene Sequences Amyloid β-Peptide: The Inside Story
Current Alzheimer Research Targeting the Nicotinic Acetylcholine Receptors (nAChRs) in Astrocytes as a Potential Therapeutic Target in Parkinson’s Disease
Current Pharmaceutical Design Structural and Functional Diversity Among Eukaryotic Hsp70 Nucleotide Exchange Factors
Protein & Peptide Letters Erythropoietin in Heart Failure and Other Cardiovascular Diseases: Hematopoietic and Pleiotropic Effects
Current Drug Targets - Cardiovascular & Hematological Disorders Editorial [Hot Topic: Progressive and Unconventional Pharmacotherapeutic Approaches to Alzheimers Disease Therapy (Guest Editors: Stuart Maudsley & Wayne Chadwick)]
Current Alzheimer Research Current Drug Targets for Modulating Alzheimer's Amyloid Precursor Protein: Role of Specific Micro-RNA Species
Current Medicinal Chemistry Mapping Chemical Space Using Molecular Descriptors and Chemical Genetics: Deacetylase Inhibitors
Combinatorial Chemistry & High Throughput Screening Glutamate Receptors in Human Caudate Nucleus in Normal Aging and Alzheimer’s Disease
Current Alzheimer Research Biosafety of Recombinant Adeno-associated Virus Vectors
Current Gene Therapy Editorial [Hot Topic: Bringing Drugs Into the Injured Brain and Keeping Them There (Executive Guest Editors: Dirk M. Hermann and Pauline Patak)]
Current Pharmaceutical Design Up-Regulation of Hypoxia-Inducible Factor (HIF)-1α and HIF-Target Genes in Cortical Neurons by the Novel Multifunctional Iron Chelator Anti-Alzheimer Drug, M30
Current Alzheimer Research The Small Heat Shock Protein HspB8: Role in Nervous System Physiology and Pathology
CNS & Neurological Disorders - Drug Targets Noradrenergic System in Down Syndrome and Alzheimer’s Disease A Target for Therapy
Current Alzheimer Research Turning REST/NRSF Dysfunction in Huntingtons Disease into a Pharmaceutical Target
Current Pharmaceutical Design Increasing Progenitor Cell Proliferation in the Sub-Ventricular Zone: A Therapeutic Treatment for Progressive Multiple Sclerosis?
Recent Patents on Drug Delivery & Formulation Editorial [Hot Topic: Regulation of Glutamate Synthesis Via Inhibition of Glutamate Carboxypeptidase II (GCPII): An Effective Method to Treat Central and Peripheral Nervous System Disorders (Guest Editors: Guido Cavaletti and Barbara Slusher)]
Current Medicinal Chemistry Pharmacophore-based Drug Design of Novel Potential Tau Ligands for Alzheimer's Disease Treatment
Current Physical Chemistry Diagnostic and Therapeutic Uses of Nanomaterials in the Brain
Current Medicinal Chemistry Subject Index To Volume 13
Current Medicinal Chemistry